ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Paclitaxel ADVAGEN, is now approved in Singapore.

“We are pleased to receive the registration approval for Paclitaxel in Singapore. We hope that with the addition of Paclitaxel, our patients and doctors will have more treatment options available to them as well.” – Soo,
Regulatory Affairs